Skip to content

Sedative synergistic effect of remifentanil combined with remimazolam intravenous general anesthesia for hysteroscopic surgery

Sedative synergistic effect of remifentanil combined with remimazolam intravenous general anesthesia for hysteroscopic surgery: a randomized and controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062983
Enrollment
Unknown
Registered
2022-08-26
Start date
2022-08-26
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

Remifentanil 2.0:Pretreatment with remifentanil 2.0 ng/mlng/ml
Remimazolam:Pretreatment with remifentanil 0 ng/ml
Remifentanil 1.0:Pretreatment with remifentanil 1.0ng/ml

Sponsors

First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-60, ASA I-III grade, who are scheduled to undergo hysteroscopic surgery; 2. Plan to send to the recovery room for resuscitation after surgery.

Exclusion criteria

Exclusion criteria: 1. Patients with severe hypertension (systolic blood pressure >= 180mmHg, or diastolic blood pressure >= 110mmHg); 2. Patients with difficult airways; 3. Patients with severe heart, liver, lung, or kidney diseases; 4. Patients with severe anemia, shock, metabolic disorders, and electrolyte disorders; 5. Pregnant women; 6. Patients who are unable to communicate; 7. Alcoholics and drug users; 8. Patients with delayed gastric retention or gastric emptying; 9. Patients who abuse hormones or anesthetic analgesics; 10. Individuals who are allergic to the studied medication.

Design outcomes

Primary

MeasureTime frame
Time of losing consciousness;

Secondary

MeasureTime frame
Characteristic of anesthesia and surgery;Vital signs;Depth of anesthesia;

Countries

China

Contacts

Public ContactXuehai Guan

First Affiliated Hospital of Guangxi Medical University

guan_xh@aliyun.com+86 18587697310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026